Physician profile
Bryan Kientz
NPI 1912381526
$5,378.43
in general payments reported to CMS, 2019-2025
28 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.13 · 2022: $528 · 2023: $1,199 · 2024: $1,923 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,763.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,024.71 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $700.53 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $613.07 | 2022-2025 | |
| Pfizer INC. | $493.01 | 2022-2025 | |
| Novo Nordisk INC | $358.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $290.94 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Eisai INC. | $285.78 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $222.83 | 2023-2025 | |
| Amgen INC. | $205.69 | 2022-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.71 | 2022-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.82 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $135.89 | 2022-2025 | |
| Dexcom, INC. | $96.27 | 2022-2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $91.91 | 2024 | |
| Ardelyx, INC. | $79.86 | 2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $54.70 | 2022-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $54.11 | 2024-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.82 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $50.27 | 2025 | Auvelity |
| Currax Pharmaceuticals LLC | $43.16 | 2022-2024 | Contrave, Onzetra Xsail |
| Sanofi-Aventis U.S. LLC | $43.16 | 2023 | |
| Philips North America LLC | $35.25 | 2022 | |
| Astellas Pharma US INC | $32.18 | 2023 | Myrbetriq |
| Phathom Pharmaceuticals, INC. | $29.05 | 2024 | Voquezna |
| Exact Sciences Corporation | $26.88 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $18.98 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $16.50 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Kientz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.